Moderna, Inc. (MRNA)
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.
Moderna Receives HHS Grant to Develop a Bird Flu Vaccine
Moderna (MRNA) shares edged higher Tuesday after the biotech firm received a federal grant to develop a vaccine to prevent bird flu in humans.
US awards Moderna $176 million to produce bird flu vaccine
The U.S. government has awarded $176 million to Moderna to advance development of its bird flu vaccine, the company said on Tuesday, as concerns rise over a multi-state outbreak of H5N1 virus in dairy cows and infections of three dairy workers since March.
Moderna gets U.S. government funding for bird-flu vaccine development
Moderna Inc.'s efforts to develop a bird-flu vaccine are getting a boost from the U.S. government, the company said Tuesday.
Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine
If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union.
Investors Who Lost Money on Moderna, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - MRNA
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Moderna, Inc. ("Moderna") (NASDAQ:MRNA) concerning possible violations of federal securities laws. Moderna issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered Yet
Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical trials.
An Investigation Has Commenced on Behalf of Moderna, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your MRNA Losses
NEW YORK, NY / ACCESSWIRE / June 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Moderna, Inc. ("Moderna") (NASDAQ:MRNA) concerning possible violations of federal securities laws. Moderna issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data
Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second year and was lower than that of rival vaccines marketed by GSK and Pfizer.
2 Stocks Down More Than 30% to Buy Right Now
Moderna recently won approval for a second product -- one with a $10 billion market. Pfizer offers a juicy dividend yield and better growth prospects than you might think.
ATTENTION Moderna, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Moderna, Inc. ("Moderna") (NASDAQ:MRNA) concerning possible violations of federal securities laws. Moderna issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
